Literature DB >> 21995400

Vemurafenib in melanoma with BRAF V600E mutation.

Jason P Lott.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21995400     DOI： 10.1056/NEJMc1108651

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

Review 1.  Dermatological adverse events from BRAF inhibitors: a growing problem.

Authors:  Viswanath Reddy Belum; Alyssa Fischer; Jennifer Nam Choi; Mario E Lacouture
Journal:  Curr Oncol Rep       Date:  2013-06       Impact factor: 5.075

2.  Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression.

Authors:  G E Piérard
Journal:  ISRN Dermatol       Date:  2012-01-11

3.  Propranolol induced G0/G1/S phase arrest and apoptosis in melanoma cells via AKT/MAPK pathway.

Authors:  Chengfang Zhou; Xiang Chen; Weiqi Zeng; Cong Peng; Gang Huang; Xian'an Li; Zhengxiao Ouyang; Yi Luo; Xuezheng Xu; Biaobo Xu; Weili Wang; Ruohui He; Xu Zhang; Liyang Zhang; Jie Liu; Todd C Knepper; Yijing He; Howard L McLeod
Journal:  Oncotarget       Date:  2016-10-18

4.  Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma.

Authors:  Kyrollis Attalla; Renzo G DiNatale; Phillip M Rappold; Christopher J Fong; Francisco Sanchez-Vega; Andrew W Silagy; Stanley Weng; Jonathan Coleman; Chung-Han Lee; Maria I Carlo; Jeremy C Durack; Stephen B Solomon; Victor E Reuter; Paul Russo; Timothy A Chan; Robert J Motzer; Nikolaus D Schultz; Ed Reznik; Martin H Voss; A Ari Hakimi
Journal:  Clin Cancer Res       Date:  2021-07-14       Impact factor: 12.531

5.  Recurrent oral cancer: current and emerging therapeutic approaches.

Authors:  Sabrina Daniela da Silva; Michael Hier; Alex Mlynarek; Luiz Paulo Kowalski; Moulay A Alaoui-Jamali
Journal:  Front Pharmacol       Date:  2012-07-30       Impact factor: 5.810
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.